Osteosarcoma

Indexed in Crossref

16 abstracts matching osteosarcoma from the meeting's journal supplement, fetched live from Crossref 2026-11-12 07:25 UTC. This is a keyword search, not the complete abstract book.

• 10032
  Comprehensive genomic landscape of osteosarcoma: Systematic review and analysis of 1,058 patients across 20 studies with therapeutic implications from the Fight Osteosarcoma Through European Research (FOSTER) Consortium.

  Emanuela Palmerini, Mathilde Bertrand, Emily M. McFarlane, Noelle Cullinan et al.
• 11524
  ICONIC (Improving Outcomes Through Collaboration in Osteosarcoma): Insights from a national prospective cohort trial for newly diagnosed osteosarcoma patients.

  Sandra J. Strauss, Bernadette Brennan, Nischalan Pillay, Adrienne Flanagan et al.
• E14596
  Targeting ALKBH5 with mefloquine as a therapeutic strategy to enhance antitumor immunity in osteosarcoma.

  Victoria Mai, Manjeet Rao
• E23502
  Surgical management and survival in pelvic osteosarcoma.

  Sebastian Respicio, Martin Phan, Christopher Reese Bine, Peter T. Silberstein et al.
• E22006
  Prognosis of mediastinal lymph node metastases in pediatric patients with osteosarcoma and lung metastases.

  Lee Ann Santore, Avantika Narasimhan, Peter Schoettler, Wendy A. Allen-Rhoades et al.
• E13540
  Uniting providers across institutions to support osteosarcoma care: Insights from 64 cases reviewed through the MIB agents TURBO board.

  Christina Ip-Toma, Matteo Maria Trucco, Bronwen Greene
• 11529
  Low-dose apatinib combination with first-line chemotherapy rechallenge in advanced osteosarcoma: A single-center ambispective cohort study.

  Jing Chen, Ting Ye, Yanfeng Jiang, Yulin Yuan et al.
• 3055
  Multi-omics discovery and clinical validation of COL1A2 alternative splicing isoforms as liquid biopsy markers for metastasis surveillance in osteosarcoma.

  Junqiang Yin, Yu Xu, Weihai Liu, Zhiqiang Zhao et al.
• 11525
  Efficacy and safety analysis of anlotinib combined with etoposide plus ifosfamide in the treatment of children and adolescents with pulmonary metastatic osteosarcoma.

  Hui Li, Kai-Li Pan, Wanliang Wu, Jing Li et al.
• TPS11586
  A phase 1b study of tegavivint, a TBL1 inhibitor, with gemcitabine in patients with relapsed or refractory osteosarcoma (TIGER).

  Thomas Cash, Rahul Aras, David D. Stenehjem, Zhulin He et al.
• 11523
  Efficacy and safety of continuous intra-arterial cisplatin and recombinant human endostatin combined with systemic chemotherapy in osteosarcoma: A phase II study.

  Hongtao Li, Chenliang Zhou, Qingyu Chen, Yan Zhou et al.
• 10016
  Characterization and validation of a methylation signature as a prognostic marker in osteosarcoma.

  Rachel M. Hurley, Cameron Cloud, Juan F. Santana, Feng Xu et al.
• 11526
  Efficacy and safety of perioperative anlotinib combined with cisplatin and doxorubicin in treatment-naive stage IIB classic osteosarcoma of the extremity: Updated results from the ALTER-S002 trial.

  Minxun Lu, Li Min, Yong Zhou, Yi Luo et al.
• 10015
  Phase II trial of olaparib and ceralasertib in patients with recurrent osteosarcoma: Lung-only resectable cohort efficacy and correlative biomarker results.

  Suzanne J. Forrest, Amanda Marinoff, J. Andrew Livingston, Kieuhoa Tran Vo et al.
• TPS11587
  A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403, a LRRC15-targeted 177 lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma.

  Noah Federman, H. David S. Ulmert, Johannes Czernin, Arun S. Singh et al.
• 10030
  Safety and feasibility of cabozantinib (CABO) in combination with cisplatin, doxorubicin, and high-dose methotrexate (MAP) in patients with newly diagnosed high-risk osteosarcoma (OS).

  Michael W. Bishop, Natalie J. DelRocco, Allen Boyd Buxton, Odion Binitie et al.